ACRV acrivon.com: ערך חשבונאי למניה

Acrivon Therapeutics is led by recognized experts who ensure the operational transparency of the innovative APAM proteomic system. The actual book value per share reflects current asset dynamics, with the metric currently standing at 2.02. A lack of sales and a dependence on test results deprive the company of pricing power. Furthermore, global conflicts are hindering reagent logistics and the execution of international research.

To select assets with a high margin of safety, analyzing net assets divided by the number of issued shares is critical. This metric objectifies the cost of capital for Acrivon Therapeutics (ACRV) by weighing AI design and synthesis automation costs against actual clinical trial expenditures, allowing for an assessment of the fair book value per share.